Pharmaceuticals and biotechnology
The typical pharmaceuticals and biotechnology company reports about 94,000 tonnes of Scope 1 and 2 emissions
71 of the 360 companies in this industry on the Data Hub report Scope 1 and 2 emissions, and 71 of them have a figure for 2023 or later, which is what the statistics below use. Figures as of November 2026.
Scope 1 and 2 are the greenhouse gases from a company’s own operations and the energy it buys; Scope 3 is everything else in its value chain. All figures are in tonnes of CO₂ equivalent (tCO₂e). Industry is the company’s sector on the SBTi registry, the Science Based Targets initiative that checks corporate climate targets.
The largest pharmaceuticals and biotechnology footprint is 34 times the industry median
Across 71 companies reporting for 2023 to 2025, the median is about 94,000 tCO₂e. A quarter of them report less than about 24,000 tCO₂e and a quarter report more than about 280,000 tCO₂e.
These are absolute footprints, so they measure a company’s size as much as its efficiency. A large company can be efficient and still sit near the top.
Scope 1 and 2 emissions, tCO₂e
- Lower quarter24,416 tCO₂e
- Median94,489 tCO₂e
- Upper quarter278,217 tCO₂e
Scope 1 and 2 emissions, tCO₂e
- Asahi Kasei Life Science Corporation3,200,000 t, 202434 times the median
- Merck & Co., Inc. (MRK)884,200 t, 20249.4 times the median
- Merck KGaA (MRK.DE)854,907 t, 20259 times the median
- Divi’s Laboratories Limited (DIVISLAB.NS)697,751 t, 20257.4 times the median
- Hetero Drugs Limited607,455 t, 20256.4 times the median
- Median94,489 t
Scope 3 usually makes up most of a company’s reported footprint
52 of the 71 companies in the statistics also report Scope 3. For the typical one, Scope 3 is 89% of its total reported footprint.
The typical reporter is cutting Scope 1 and 2 emissions year on year
Among 63 companies with two recent years, the median change is a fall of 9.8% a year. The SBTi cross-sector pathway for 1.5°C asks for about 4.2% less each year.
Average change a year, compound
- Pharmaceuticals and biotechnologydown 9.8% a year
- SBTi 1.5°C referencedown 4.2% a year
Most companies in this industry have targets checked by the SBTi
220 of the 360 companies have near-term targets validated by the SBTi, and 216 of those are aligned with 1.5°C. 71 also have a validated net-zero target, and 5 companies have had a commitment removed. The median near-term target year is 2030.
- Targets validated: 220
- Committed: 135
- Commitment removed: 5
Some companies in this industry also retire carbon credits
35 companies in this industry retired about 830,000 tonnes of carbon credits since November 2024. Retiring a credit uses it up so that no one else can claim it. The largest project types are forest, GHG management and renewable energy.
Retirements come from public registries (CarbonPlan and VROD) and cover November 2024 onward, matched to companies by name, so a missing figure does not mean a company never retired credits.
Every reporting company, largest Scope 1 and 2 footprint first
Emissions in tCO₂e for the latest year each company reports. 289 more companies in this industry have no Scope 1 and 2 figure on file yet.
- Asahi Kasei Life Science Corporation
Scope 1 and 2: 3,200,000 tCO₂e in 2024
SBTi near-term: Targets validated
- Merck & Co., Inc. (MRK)
Scope 1 and 2: 884,200 tCO₂e in 2024
SBTi near-term: Targets validated
- Merck KGaA (MRK.DE)
Scope 1 and 2: 854,907 tCO₂e in 2025
SBTi near-term: Targets validated
- Divi’s Laboratories Limited (DIVISLAB.NS)
Scope 1 and 2: 697,751 tCO₂e in 2025
SBTi near-term: Targets validated
- Hetero Drugs Limited
Scope 1 and 2: 607,455 tCO₂e in 2025
SBTi near-term: Targets validated
- Apeloa Pharmaceutical Co., Ltd. (000739.SZ)
Scope 1 and 2: 564,411 tCO₂e in 2025
SBTi near-term: Committed
- WuXi AppTec Co., Ltd. (2359.HK)
Scope 1 and 2: 536,652 tCO₂e in 2025
SBTi near-term: Targets validated
- Thermo Fisher Scientific Inc. (TMO)
Scope 1 and 2: 475,046 tCO₂e in 2025
SBTi near-term: Targets validated
- Teva Pharmaceutical Industries Ltd. (TEVA)
Scope 1 and 2: 462,107 tCO₂e in 2024
SBTi near-term: Targets validated
- Lonza Group Ltd (LONN)
Scope 1 and 2: 410,000 tCO₂e in 2025
SBTi near-term: Targets validated
- AbbVie Inc. (ABBV)
Scope 1 and 2: 380,850 tCO₂e in 2025
SBTi near-term: Targets validated
- Johnson & Johnson (JNJ)
Scope 1 and 2: 358,133 tCO₂e in 2025
SBTi near-term: Targets validated
- Dr. Reddy's Laboratories Limited (RDY)
Scope 1 and 2: 339,081 tCO₂e in 2025
SBTi near-term: Targets validated
- Lupin Limited (LUPIN.NS)
Scope 1 and 2: 332,149 tCO₂e in 2025
SBTi near-term: Targets validated
- Bristol-Myers Squibb Company (BMY)
Scope 1 and 2: 311,375 tCO₂e in 2024
SBTi near-term: Targets validated
- Ipca Laboratories Limited (IPCALAB)
Scope 1 and 2: 302,144 tCO₂e in 2025
SBTi near-term: Committed
- CSL Limited (CSL)
Scope 1 and 2: 286,000 tCO₂e in 2025
SBTi near-term: Targets validated
- Shandong Xinhua Pharmaceutical Company Limited (719)
Scope 1 and 2: 282,434 tCO₂e in 2025
SBTi near-term: Committed
- Takeda Pharmaceutical Company Limited (TAK)
Scope 1 and 2: 274,000 tCO₂e in 2025
SBTi near-term: Targets validated
- Labcorp Holdings Inc. (LH)
Scope 1 and 2: 268,371 tCO₂e in 2025
SBTi near-term: Targets validated
- Zydus Lifesciences Limited (ZYDUSLIFE.NS)
Scope 1 and 2: 261,631 tCO₂e in 2025
SBTi near-term: Committed
- WuXi Biologics (Cayman) Inc. (WXXWY)
Scope 1 and 2: 229,730 tCO₂e in 2025
SBTi near-term: Targets validated
- Roche Holding AG (ROG)
Scope 1 and 2: 220,491 tCO₂e in 2025
SBTi near-term: Targets validated
- Novartis AG (NVS)
Scope 1 and 2: 207,200 tCO₂e in 2025
SBTi near-term: Targets validated
- Pharmaron Beijing Co., Ltd. (3759.HK)
Scope 1 and 2: 198,701 tCO₂e in 2024
SBTi near-term: Targets validated
- McKesson Corporation (MCK)
Scope 1 and 2: 192,158 tCO₂e in 2025
SBTi near-term: Targets validated
- Sandoz Group AG (SDZ.SW)
Scope 1 and 2: 182,200 tCO₂e in 2025
SBTi near-term: Targets validated
- Amgen Inc. (AMGN)
Scope 1 and 2: 161,000 tCO₂e in 2024
SBTi near-term: Targets validated
- GenScript Biotech Corporation (1548.HK)
Scope 1 and 2: 153,412 tCO₂e in 2024
SBTi near-term: Targets validated
- AstraZeneca plc (AZN)
Scope 1 and 2: 139,596 tCO₂e in 2024
SBTi near-term: Targets validated
- Otsuka Holdings Co., Ltd. (4578.T)
Scope 1 and 2: 111,134 tCO₂e in 2023
SBTi near-term: Committed
- Daiichi Sankyo Company, Limited (4568.T)
Scope 1 and 2: 103,735 tCO₂e in 2025
SBTi near-term: Targets validated
- Les Laboratoires Servier
Scope 1 and 2: 103,149 tCO₂e in 2024
SBTi near-term: Targets validated
- Charles River Laboratories International, Inc. (CRL)
Scope 1 and 2: 102,610 tCO₂e in 2024
SBTi near-term: Targets validated
- Fabbrica Italiana Sintetici S.p.A.
Scope 1 and 2: 98,251 tCO₂e in 2025
SBTi near-term: Targets validated
- Biocon Biologics Limited
Scope 1 and 2: 94,489 tCO₂e in 2025
SBTi near-term: Targets validated
- Glenmark Pharmaceuticals Limited (GLENMARK)
Scope 1 and 2: 85,087 tCO₂e in 2024
SBTi near-term: Targets validated
- Astellas Pharma Inc. (4503)
Scope 1 and 2: 80,914 tCO₂e in 2025
SBTi near-term: Targets validated
- Gilead Sciences, Inc. (GILD)
Scope 1 and 2: 70,993 tCO₂e in 2024
SBTi near-term: Targets validated
- Avantor, Inc. (AVTR)
Scope 1 and 2: 68,069 tCO₂e in 2025
SBTi near-term: Targets validated
- Shionogi & Co., Ltd. (4507.T)
Scope 1 and 2: 63,057 tCO₂e in 2024
SBTi near-term: Targets validated
- Sartorius AG (SRT3)
Scope 1 and 2: 57,158 tCO₂e in 2025
SBTi near-term: Targets validated
- Hikal Limited (HIKAL.NS)
Scope 1 and 2: 53,710 tCO₂e in 2025
SBTi near-term: Committed
- IOL Chemicals and Pharmaceuticals Ltd (IOLCP)
Scope 1 and 2: 51,940 tCO₂e in 2025
SBTi near-term: Targets validated
- Chugai Pharmaceutical Co., Ltd. (4519.T)
Scope 1 and 2: 50,342 tCO₂e in 2025
SBTi near-term: Targets validated
- Bespak Limited
Scope 1 and 2: 48,390 tCO₂e in 2025
SBTi near-term: Targets validated
- Sumitomo Pharma Co., Ltd. (4506.T)
Scope 1 and 2: 46,258 tCO₂e in 2024
SBTi near-term: Targets validated
- Guerbet SA (GBT)
Scope 1 and 2: 44,100 tCO₂e in 2025
SBTi near-term: Targets validated
- Eisai Co., Ltd. (4523.T)
Scope 1 and 2: 43,907 tCO₂e in 2025
SBTi near-term: Targets validated
- Aragen Life Sciences Limited
Scope 1 and 2: 40,516 tCO₂e in 2024
SBTi near-term: Targets validated
- Almac Group Limited
Scope 1 and 2: 30,162 tCO₂e in 2023
SBTi near-term: Targets validated
- H. Lundbeck A/S (HLUNB)
Scope 1 and 2: 27,497 tCO₂e in 2024
SBTi near-term: Targets validated
- Syngene International Limited (SYNGENE)
Scope 1 and 2: 24,768 tCO₂e in 2023
SBTi near-term: Targets validated
- Edwards Lifesciences Corporation (EW)
Scope 1 and 2: 24,064 tCO₂e in 2024
SBTi near-term: Targets validated
- Evotec SE (EVO)
Scope 1 and 2: 20,669 tCO₂e in 2024
SBTi near-term: Targets validated
- QIAGEN N.V. (QGEN)
Scope 1 and 2: 20,618 tCO₂e in 2025
SBTi near-term: Targets validated
- Bio-Techne Corporation (TECH)
Scope 1 and 2: 18,512 tCO₂e in 2024
SBTi near-term: Targets validated
- Tabuk Pharmaceuticals Manufacturing Company
Scope 1 and 2: 17,262 tCO₂e in 2024
SBTi near-term: Targets validated
- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
Scope 1 and 2: 13,061 tCO₂e in 2024
SBTi near-term: Targets validated
- Azenta, Inc. (AZTA)
Scope 1 and 2: 10,850 tCO₂e in 2025
SBTi near-term: Targets validated
- Ono Pharmaceutical Co., Ltd. (4528.T)
Scope 1 and 2: 9,700 tCO₂e in 2025
SBTi near-term: Targets validated
- Illumina, Inc. (ILMN)
Scope 1 and 2: 8,943 tCO₂e in 2025
SBTi near-term: Targets validated
- BioNTech SE (BNTX)
Scope 1 and 2: 8,003 tCO₂e in 2025
SBTi near-term: Targets validated
- Bachem Holding AG (BANB)
Scope 1 and 2: 5,564 tCO₂e in 2025
SBTi near-term: Targets validated
- Guardant Health, Inc. (GH)
Scope 1 and 2: 3,991 tCO₂e in 2025
SBTi near-term: Targets validated
- Parexel International Corporation
Scope 1 and 2: 2,705 tCO₂e in 2024
SBTi near-term: Targets validated
- Ardena Holding NV
Scope 1 and 2: 1,807 tCO₂e in 2024
SBTi near-term: Committed
- Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Scope 1 and 2: 1,465 tCO₂e in 2025
SBTi near-term: Targets validated
- HitGen Inc. (688222.SH)
Scope 1 and 2: 1,409 tCO₂e in 2025
SBTi near-term: Committed
- Suven Life Sciences Limited (SUVEN)
Scope 1 and 2: 916 tCO₂e in 2025
SBTi near-term: Targets validated
- ProductLife Group
Scope 1 and 2: 400 tCO₂e in 2025
SBTi near-term: Targets validated
Method
- Industry is the sector of each company’s primary record on the SBTi registry. Companies outside the SBTi registry have no industry page.
- Statistics use each company’s latest Scope 1 and 2 figure, and only when it is for 2023 or later, so older years are listed but not pooled with recent ones.
- A median appears once at least 10 companies report, and quartiles once at least 20 do. Below that, companies are listed without statistics.
- Figures of zero for both Scope 1 and 2, above 100 million tonnes for Scope 1 and 2, or above a billion tonnes for Scope 3 are listed with a review tag and left out of statistics.
- Company pages that Carbon3 prepared ahead of a claim are left out of industry statistics.
- A missing figure is shown as not reported, never as zero, and nothing is estimated.
- The year-on-year change compares a company’s latest figure with its previous one, up to three years earlier, as a yearly rate.
Sources: company filings via the Carbon3 emissions registry (each figure links to its filing), the SBTi target dashboard, and the CarbonPlan and VROD retirement registries; Carbon3 analysis.
Questions about the data, or a company to add?
Contact us